Pharma Watch: Dayno Named Medical Chief At Labopharm

May 6, 2010 (FinancialWire) — Labopharm Inc. (TSX: DDS) (NASDAQ: DDSS) has appointed Jeffrey M. Dayno, M.D. as its chief medical officer. Dayno will be responsible for leading the clinical activities for Labopharm's drug development programs, as well as overseeing the company's medical affairs functions, including medical information and pharmacovigilance, for all commercialized products.

He will be based out of Labopharm's U.S. office in Princeton, New Jersey.

Dayno joins Labopharm from Cephalon, Inc. (NASDAQ: CEPH), where he was VP of medical services overseeing a team of medical directors in support of commercial franchises.

Prior to his tenure at Cephalon, Dayno spent seven years with Merck & Co., Inc. in medical services positions, culminating in his role as senior director of medical services for U.S. medical and scientific affairs.

Labopharm is headquartered in Laval, Canada with U.S. offices in Princeton, New Jersey. The company is focused on optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The company's lead product, a unique once-daily formulation of tramadol, is available in 19 countries around the world, including the U.S., Canada, major European markets and Australia.

Labopharm’s second product, Oleptro, a novel formulation of trazodone for the treatment of major depressive disorder in adults, has received regulatory approval in the U.S. and is under regulatory review in Canada.

Labopharm has initiated the European regulatory approval process for its third product, a twice-daily formulation of tramadol-acetaminophen. The company also has a pipeline of follow-on products in both pre-clinical and clinical development.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [biomedphrm] [cndnexh] [clvloy]